on EUROMEDIS GROUPE (EPA:ALEMG)
Euromedis Group: 2024 Annual Results
The Euromedis Group Board of Directors closed the accounts for the 2024 financial year on April 25, 2025. The year was marked by the liquidation of the Gaillard Group, resulting in a €6 million impairment charge recorded as exceptional expenses. Despite this, revenue increased by 6% to €36.2 million. However, net income plunged to -€6.1 million.
The company has suffered from volatile transportation costs, particularly due to geopolitical tensions in the Middle East. These factors have lengthened supply lead times and increased cost volatility. In 2025, Euromedis is seeking to diversify its activities, with a focus on exports to reduce its reliance on public procurement.
The logistics reorganization initiated in 2024 is expected to generate savings. However, profitability in 2025 will depend on global geopolitical developments.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EUROMEDIS GROUPE news